Skip Navigation LinksHome > September 2013 - Volume 2 - Issue 3 > Growth hormone axis in patients with ST elevation myocardial...
Cardiovascular Endocrinology:
doi: 10.1097/XCE.0b013e328362e436
Short report

Growth hormone axis in patients with ST elevation myocardial infarction and non-ST elevation myocardial infarction.

Dizdarević-Hudić, Larisaa; Kusljugić, Zumretaa; Baraković, Fahira; Hajder, Mithadb; Isabegovic, Maidaa; Hudić, Igorc; Smajić, Elnura; Iveljić, Ivanaa

Collapse Box

Abstract

We investigated the insulin-like growth factor 1 (IGF-1)/growth hormone (GH) axis in patients with ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). This was a prospective study that was carried out in 2010. The study included an analysis of levels of GH, insulin, IGF-1, and its binding protein (IGFBP-3) in 43 patients with STEMI, 30 patients with NSTEMI, and 30 healthy individuals (control group). Blood samples for all analyses were taken within 24 h of admission. We found lower IGF-1 and IGFBP-3 levels and higher GH, C-reactive protein, glucose, and glycol glycosylated hemoglobin (HbA1c) levels in both STEMI and NSTEMI patients compared with controls. Insulin levels and the insulin resistance index did not differ between NSTEMI patients and controls. A significant difference in GH values was observed between the STEMI and NSTEMI groups (P<0.05). The increased GH levels in the STEMI compared with the NSTEMI group are consistent with a stronger inflammatory response in patients with STEMI.

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.